Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 20/20 | 1.00 |
| ▸ | GNA15 | P30679 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13118205 | 1.00 | FFAR1 (1.00) | FFAR1GNA15 | |
| SCHEMBL12194429 | 1.00 | FFAR1 (1.00) | FFAR1GNA15 | |
| SCHEMBL29367214 | 1.00 | FFAR1 (1.00) | FFAR1GNA15 | |
| SCHEMBL3518942 | 0.99 | FFAR1 (0.98) | FFAR1GNA15 | |
| SCHEMBL5297901 | 0.99 | FFAR1 (0.98) | FFAR1GNA15 | |
| SCHEMBL18884086 | 0.94 | FFAR1 (0.88) | FFAR1GNA15 | |
| SCHEMBL13118209 | 0.93 | FFAR1 (0.88) | FFAR1GNA15 | |
| SCHEMBL12191648 | 0.93 | FFAR1 (0.86) | FFAR1GNA15 | |
| SCHEMBL3518944 | 0.92 | FFAR1 (0.84) | FFAR1GNA15 | |
| SCHEMBL5297906 | 0.92 | FFAR1 (0.84) | FFAR1GNA15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246470-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2019-04-02 | — | — | US | disclosed |
| US-10011609-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2018-07-03 | — | — | US | disclosed |
| US-20160257701-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2016-09-08 | — | — | US | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | GOT2, PC, GLS2 | FFAR1 549/4885GNA15 3737/4885 |
| US-10011609-B2 | Heterocyclic compounds | GPR55, GPR68, GPR65 | FFAR1 27/4885GNA15 514/4885 |
| US-10246470-B2 | Heterocyclic compounds | HAAO, HK1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | FFAR1 2831/4885GNA15 3995/4885 |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | GOT2, GLS2, PC | FFAR1 699/4885GNA15 3680/4885 |
| US-20160257701-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GPR55, GPR68, GPR65 | FFAR1 23/4885GNA15 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.